Re: Yeh et al.: Ophthalmic Technology Assessment: therapies for macular edema associated with central retinal vein occlusion: a report by the American Academy of Ophthalmology (Ophthalmology 2015;122:769-78)

In their review, Yeh et al1 thoroughly assessed the available evidence regarding the safety and efficacy of therapies for macular edema (ME) associated with central retinal vein occlusion (CRVO). Of the treatments evaluated, anti-vascular endothelial grow factor (VEGF) pharmacotherapy was the most common intervention. The authors conducted an excellent comprehensive presentation and discussion of the Cruise, Copernicus, Galileo, and Swedish trials, providing level 1 evidence supporting the use of intravitreal injections with ranibizumab (Lucentis, Genentech, Inc., South San Francisco, CA), aflibercept (IVA; Eylea, Regeneron Pharmaceuticals, Inc., Tarrytown, NY), and bevacizumab (Avastin, Genentech, Inc., San Francisco, CA) in patients with ME after CRVO.